Grown Rogue International (GRUSF) Income towards Parent Company (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Income towards Parent Company came in at -$2.2 million in Q1 2026, down 320.16% year-on-year from $1.0 million in Q1 2025, and up 100.0% quarter-over-quarter from -$5914.4 billion in Q4 2025.
Grown Rogue International (GRUSF) Income towards Parent Company (2009 - 2026) Analysis & Trends
Grown Rogue International's Income towards Parent Company history runs 18 years deep, the most recent figure standing at -$2.2 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 320.16% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$3216.1 billion, a 302.76% decrease from a year earlier, with the FY2025 full-year figure at -$2.1 million, up 81.27% from the prior year.
- Income towards Parent Company advanced to -$2.2 million in Q1 2026 per GRUSF's latest filing, from -$5914.4 billion in the prior quarter.
- Across five years, Income towards Parent Company topped out at $2698.3 billion in Q3 2025 and bottomed at -$5914.4 billion in Q4 2025.
- The 5-year median for Income towards Parent Company is -$4989.0 (2022), against an average of -$286.8 billion.
- Across the five-year window, Income towards Parent Company jumped 437.92% in 2025 and plunged 320.16% in 2026, its largest moves.
- Year by year, Income towards Parent Company stood at -$422824.0 in 2022, then jumped by 252.03% to $642820.0 in 2023, then plunged by 124220877.2% to -$798.5 billion in 2024, then slumped by 640.68% to -$5914.4 billion in 2025, then surged by 100.0% to -$2.2 million in 2026.
- Per Business Quant, the three latest GRUSF Income towards Parent Company figures stand at -$2.2 million (Q1 2026), -$5914.4 billion (Q4 2025), and $2698.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.21 Mn |
| Dec 31, 2025 | -5,914.43 Bn |
| Sep 30, 2025 | 2,698.31 Bn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Sep 30, 2024 | -798.52 Bn |
| Jun 30, 2024 | -5.62 Mn |
| Mar 31, 2024 | -4.20 Mn |
| Dec 31, 2023 | 642,820.00 |
| Oct 31, 2023 | -1.47 Mn |
| Jul 31, 2023 | 640,713.00 |
| Apr 30, 2023 | 412,846.00 |
| Jan 31, 2023 | 931,945.00 |
| Jan 31, 2022 | -422,824.00 |
| Jul 31, 2021 | -54,533.00 |
| Apr 30, 2021 | -1.43 Mn |
| Jan 31, 2021 | -1.08 Mn |
| Oct 31, 2020 | 26,352.00 |
| Jul 31, 2020 | -798,200.00 |
| Apr 30, 2020 | -1.28 Mn |